TxCell Share Price

Stocks

TXCL

FR0010127662

Biotechnology & Medical Research

Real-time Euronext Paris 5-day change 1st Jan Change
- EUR -.--% Intraday chart for TxCell -.--% +67.53%
Manager TitleAgeSince
Chief Operating Officer 50 -
Corporate Officer/Principal - -
Corporate Officer/Principal - -
Director TitleAgeSince
Chairman - 11/02/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
+2.35%+2.74%+38.10%+74.02% 56.54B
-0.94%-6.58%+25.56%+62.15% 53.6B
-2.44%+1.40%-15.61%-13.72% 22.91B
-2.85%-7.78%-9.28%+352.92% 21.37B
+0.15%+0.36%+24.28%-14.44% 20.27B
+0.50%-2.04%+32.18%-28.96% 17.56B
-1.45%-7.15%+17.96%+554.50% 14.75B
+3.41%-6.61%+162.81%+287.77% 13.53B
-5.25%-4.23%+42.32%+160.72% 13.33B
Average -0.66%-3.79%+35.37%+159.44% 25.98B
Weighted average by Cap. -0.30%-2.96%+30.18%+120.40%
Logo TxCell
TxCell is a biotechnology company which develops platforms for innovative customized cell immunotherapies from regulatory T cells (Treg) for the treatment of severe chronic inflammatory, autoimmune diseases and transplant rejection. TxCell is developing a platform for genetically modified T-cells, the CAR-Tregs. TxCell plans to release preclinical proof-of-concept data in 2017 and start a first clinical study by the end of 2018.
Employees
-
  1. Stock Market
  2. Stocks
  3. TXCL Stock